Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

Cephalalgia

Volumn 34, Issue 11, 2014, Pages 853-869

  Burstein, Rami ^a,b   Zhang, XiChun ^a,b   Levy, Dan ^a,b   Aoki, K Roger ^c   Brin, Mitchell F ^c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Headache; High threshold mechanosensitive ion channels; Nociception; Pain; TRPA1; TRPV1

Indexed keywords

BOTULINUM TOXIN A; NEUROTOXIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; DURA MATER; ELECTROPHYSIOLOGICAL PROCEDURES; MALE; MECHANICAL STIMULATION; MIGRAINE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN; PAIN RECEPTOR; RAT; RECEPTIVE FIELD; SENSITIZATION; SKULL SUTURE; TOPICAL TREATMENT; TREATMENT INDICATION; TRIGEMINAL NUCLEUS; ANIMAL; DRUG EFFECTS; ELECTROPHYSIOLOGY; MECHANOTRANSDUCTION; MENINX; MICROELECTRODE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BOTULINUM TOXINS, TYPE A; ELECTROPHYSIOLOGY; MALE; MECHANOTRANSDUCTION, CELLULAR; MENINGES; MICROELECTRODES; MIGRAINE DISORDERS; NEUROTOXINS; NOCICEPTORS; PAIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84908231844     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414527648     Document Type: Article

References (88)

1. Julius D and Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-210.
2. Levine JD and Reichling DB. Peripheral mechanisms of inflammatory pain. In: Wall PD, Melzack R (eds) Textbook of pain, 4th edn. New York: Churchill Livingstone, 1999, pp.59-84.
3. Davis KD, Meyer RA and Campbell JN. Chemosensitivity and sensitization of nociceptive afferents that innervate the hairy skin of monkey. J Neurophysiol 1993; 69: 1071-1081.
4. Kosaras B, Jakubowski M, Kainz V, et al. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol 2009; 515: 331-348.
5. Martin HA, Basbaum AI, Kwiat GC, et al. Leukotriene and prostaglandin sensitization of cutaneous high-threshold C- and A-delta mechanonociceptors in the hairy skin of rat hindlimbs. Neuroscience 1987; 22: 651-659.
6. Su X and Gebhart GF. Mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat are polymodal in character. J Neurophysiol 1998; 80: 2632-2644.
7. McMahon SB, Lewin GR and Wall PD. Central hyperexcitability triggered by noxious inputs. Curr Opin Neurobiol 1993; 3: 602-610.
8. Woolf CJ. Somatic pain-pathogenesis and prevention. Br J Anaesth 1995; 75: 169-176.
9. Woolf CJ and Doubell TP. The pathophysiology of chronic pain - increased sensitivity to low threshold A beta-fibre inputs. Curr Opin Neurobiol 1994; 4: 525-534.
10. Zhang X, Levy D, Kainz V, et al. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 2011; 69: 855-865.
11. Zhang XC, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: Implications to migraine with aura. J Neurosci 2010; 30: 8807-8814.
12. Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130: 166-176.
13. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16: 157-168.
14. Moskowitz MA and Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993; 5: 159-177.
15. Yan J, Edelmayer RM, Wei X, et al. Dural afferents express acid-sensing ion channels: A role for decreased meningeal pH in migraine headache. Pain 2011; 152: 106-113.
16. Fabbretti E, D'Arco M, Fabbro A, et al. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci 2006; 26: 6163-6171.
17. Clark ME. Post-deployment pain: A need for rapid detection and intervention. Pain Med 2004; 5: 333-334.
18. Gawande A. Casualties of war - military care for the wounded from Iraq and Afghanistan. N Engl J Med 2004; 351: 2471-2475.
19. Gironda RJ, Clark ME, Massengale JP, et al. Pain among veterans of Operations Enduring Freedom and Iraqi Freedom. Pain Med 2006; 7: 339-343.
20. Huang D, Li S, Dhaka A, et al. Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. Mol Pain 2012; 8: 66.
21. Staikopoulos V, Sessle BJ, Furness JB, et al. Localization of P2X2 and P2X3 receptors in rat trigeminal ganglion neurons. Neuroscience 2007; 144: 208-216.
22. Cavallotti C, Frati A, Cavallotti D, et al. Dopaminergic receptors in rat dura mater: Pharmacological characteristics. Clin Exp Pharmacol Physiol 2004; 31: 190-194.
23. Harriott AM and Gold MS. Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia 2008; 28: 933-944.
24. Harriott AM and Gold MS. Electrophysiological properties of dural afferents in the absence and presence of inflammatory mediators. J Neurophysiol 2009; 101: 3126-3134.
25. Eftekhari S, Warfvinge K, Blixt FW, et al. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 2013; 14: 1289-1303.
26. Zhang XC, Kainz V, Burstein R, et al. Tumor necrosis factor-alpha induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain 2011; 152: 140-149.
27. Lazarov NE. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol 2002; 66: 19-59.
28. Schueler M, Messlinger K, Dux M, et al. Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache. Pain 2013; 154: 1622-1631.
29. Schüler M, Messlinger K, Neuhuber W, et al. Comparative anatomy of the trigeminal nerve fibres in the middle cranial fossa and their extracranial projections in rats and humans. Presented at 15th Congress of the International Headache Society, 23-26 June 2011, Berlin, Germany.
30. Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 2013; 339: 1092-1095.
31. Strassman AM, Raymond SA and Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560-564.
32. Levy D, Burstein R and Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine. Ann Neurol 2005; 58: 698-705.
33. Blau JN and Dexter SL. The site of pain origin during migraine attacks. Cephalalgia 1981; 1: 143-147.
34. Rasmussen BK, Jensen R and Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991; 11: 129-134.
35. Liveing E. On megrim, sick-headache, and some allied disorders: A contribution to the pathology of nerve-storms, 1873. Nijmegen, The Netherlands: Arts & Boeve Publishers, 1997.
36. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-624.
37. Selby G and Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiat 1960; 23: 23-32.
38. Wolff HG, Tunis MM and Goodell H. Studies on migraine. Arch Intern Med 1953; 92: 478-484.
39. Waelkens J. Warning symptoms in migraine: Characteristics and therapeutic implications. Cephalalgia 1985; 5: 223-228.
40. Jensen K, Tuxen C and Olesen J. Pericranial muscle tenderness and pressure-pain threshold in the temporal region during common migraine. Pain 1988; 35: 65-70.
41. Lous I and Olesen J. Evaluation of pericranial tenderness and oral function in patients with common migraine, muscle contraction headache and 'combination headache'. Pain 1982; 12: 385-393.
42. Burstein R, Yamamura H, Malick A, et al. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998; 79: 964-982.
43. Ashkenazi A and Young WB. Dynamic mechanical (brush) allodynia in cluster headache. Headache 2004; 44: 1010-1012.
44. Lopinto C, Young W and Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 2006; 26: 852-856.
45. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008; 63: 148-158.
46. Mathew NT, Kailasam J and Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004; 63: 848-852.
47. Weissman-Fogel I, Sprecher E, Granovsky Y, et al. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: Clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain 2003; 104: 693-700.
48. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64: 274-283.
49. Luvisetto S, Marinelli S, Cobianchi S, et al. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007; 145: 1-4.
50. Kamanli A, Kaya A, Ardicoglu O, et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005; 25: 604-611.
51. Cheshire WP, Abashian SW and Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65-69.
52. Gazerani P, Staahl C, Drewes AM, et al. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006; 122: 315-325.
53. Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007; 130: 76-83.
54. Voller B, Sycha T, Gustorff B, et al. Arandomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003; 61: 940-944.
55. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002; 205: 59-63.
56. Stucky CL, Dubin AE, Jeske NA, et al. Roles of transient receptor potential channels in pain. Brain Res Rev 2009; 60: 2-23.
57. Lennertz RC, Kossyreva EA, Smith AK, et al. TRPA1 mediates mechanical sensitization in nociceptors during inflammation. PLoS One 2012; 7: e43597.
58. Smith AK, O'Hara CL and Stucky CL. Mechanical sensitization of cutaneous sensory fibers in the spared nerve injury mouse model. Mol Pain 2013; 9: 61.
59. Garrison SR, Dietrich A and Stucky CL. TRPC1 contributes to light-touch sensation and mechanical responses in low-threshold cutaneous sensory neurons. J Neurophysiol 2012; 107: 913-922.
60. Garrison SR, Kramer AA, Gerges NZ, et al. Sickle cell mice exhibit mechanical allodynia and enhanced responsiveness in light touch cutaneous mechanoreceptors. Mol Pain 2012; 8: 62.
61. Kwan KY, Allchorne AJ, Vollrath MA, et al. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 2006; 50: 277-289.
62. Petrus M, Peier AM, Bandell M, et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 2007; 3: 40.
63. Drew LJ, Rugiero F, Cesare P, et al. High-threshold mechanosensitive ion channels blocked by a novel conopeptide mediate pressure-evoked pain. Plos One 2007; 2: e515.
64. Paterson K, Lolignier S, Wood JN, et al. Botulinum Toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol. Epub ahead of print 18 February 2014. DOI: 10.1002/ana.24122.
65. Kim SE, Coste B, Chadha A, et al. The role of Drosophila Piezo in mechanical nociception. Nature 2012; 483: 209-212.
66. Coste B, Mathur J, Schmidt M, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science 2010; 330: 55-60.
67. Coste B, Xiao B, Santos JS, et al. Piezo proteins are pore-forming subunits of mechanically activated channels. Nature 2012; 483: 176-181.
68. Nilius B and Honore E. Sensing pressure with ion channels. Trends Neurosci 2012; 35: 477-486.
69. Royle SJ and Murrell-Lagnado RD. Constitutive cycling: A general mechanism to regulate cell surface proteins. Bioessays 2003; 25: 39-46.
70. Takamori S, Holt M, Stenius K, et al. Molecular anatomy of a trafficking organelle. Cell 2006; 127: 831-846.
71. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004; 279: 25665-25672.
72. Camprubí-Robles M, Planells-Cases R and Ferrer-Montiel A. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J 2009; 23: 3722-3733.
73. Camprubí-Robles M, Ferrer-Montiel A and Planells-Cases R. Contribution of ion channel trafficking to nociceptor sensitization. Open Pain J 2010; 3: 108-116.
74. Shimizu T, Shibata M, Toriumi H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012; 48: 367-378.
75. Radresa O, Pare M and Albert JS. Multiple roles of transient receptor potential (TRP) channels in inflammatory conditions and current status of drug development. Curr Top Med Chem 2013; 13: 367-385.
76. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001; 22: 182-188.
77. Chen CC, Akopian AN, Sivilotti L, et al. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 1995; 377: 428-431.
78. Jennings EA and Cho H-J. Peripheral sensitization in migraine-role for P2X purinergic receptors in the dura-vascular sensory pathway. Drug Devel Res 2007; 68: 321-328.
79. Lewis C, Neidhart S, Holy C, et al. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 1995; 377: 432-435.
80. Schmidt M, Dubin AE, Petrus MJ, et al. Nociceptive signals induce trafficking of TRPA1 to the plasma membrane. Neuron 2009; 64: 498-509.
81. Apostolidis A, Dasgupta P and Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-650.
82. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-982. (discussion 82-83).
83. Kanai AJ. Afferent mechanism in the urinary tract. Handb Exp Pharmacol 2011; 171-205.
84. Vianello A, Proietti S and Giannantoni A. Effect of botulinum neurotoxin on the urinary bladder: Novel insights on mechanism of action. Minerva Urol Nefrol 2010; 62: 259-271.
85. Jahn R and Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature 2012; 490: 201-207.
86. Sudhof TC. The synaptic vesicle cycle. Annu Rev Neurosci 2004; 27: 509-547.
87. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707-1714.
88. Singh JA. Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Ther Adv Musculoskelet Dis 2010; 2: 105-118.